AXSM - Baird starts Axsome at outperform cites upcoming data
2024-03-19 14:16:52 ET
More on Axsome Therapeutics
- Axsome: Unpacking Auvelity's First-Year Market Dynamics And Economic Challenges
- Axsome Therapeutics, Inc. (AXSM) Q4 2023 Earnings Call Transcript
- Axsome: Show Me Another Company With Such A Stack Of Catalysts
- Axsome Therapeutics Q4 2023 Earnings Preview
- UBS starts Axsome at buy, sees Auvelity hitting $1B sales by 2030